Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease

[1]  J. A. López-Moreno,et al.  The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction , 2008, Addiction biology.

[2]  Jess Nithianantharajah,et al.  Gene–environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington’s disease transgenic mice , 2008, Neurobiology of Disease.

[3]  T. Bisogno,et al.  Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease , 2008, Neurochemistry International.

[4]  A. Finazzi-Agro’,et al.  Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes , 2007, Neurobiology of Disease.

[5]  D. Centonze,et al.  The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases , 2007, Progress in Neurobiology.

[6]  S. Nigam,et al.  Biochemistry and pharmacology of endovanilloids. , 2007, Pharmacology & therapeutics.

[7]  Nathan C. Stam,et al.  Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in huntington’s disease transgenic mice , 2006, Neuroscience.

[8]  H. Bradshaw,et al.  Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[9]  A. Grace,et al.  The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction , 2006, Cellular and Molecular Life Sciences CMLS.

[10]  Mauro Maccarrone,et al.  Abnormal Sensitivity to Cannabinoid Receptor Stimulation Might Contribute to Altered Gamma-Aminobutyric Acid Transmission in the Striatum of R6/2 Huntington’s Disease Mice , 2005, Biological Psychiatry.

[11]  L. Csiba,et al.  Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. , 2005, Brain research. Molecular brain research.

[12]  C. Blakemore,et al.  Deficits in Experience-Dependent Cortical Plasticity and Sensory-Discrimination Learning in Presymptomatic Huntington's Disease Mice , 2005, The Journal of Neuroscience.

[13]  E Sylvester Vizi,et al.  Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis , 2005, The Journal of Neuroscience.

[14]  C. Blakemore,et al.  Delayed onset of huntington′s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors , 2004, Neuroscience.

[15]  Carlos Cepeda,et al.  Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF , 2004, Journal of neuroscience research.

[16]  Haibei Hu,et al.  Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. , 2004, European journal of biochemistry.

[17]  C. Blakemore,et al.  Environmental Enrichment Rescues Protein Deficits in a Mouse Model of Huntington's Disease, Indicating a Possible Disease Mechanism , 2004, The Journal of Neuroscience.

[18]  K. Fenger,et al.  Molecular and behavioral analysis of the r6/1 huntington′s disease transgenic mouse , 2003, Neuroscience.

[19]  M. Elphick,et al.  Comparative analysis of fatty acid amide hydrolase and cb1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling , 2003, Neuroscience.

[20]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.

[21]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[22]  G. Reynolds,et al.  The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease , 2002, Journal of neurochemistry.

[23]  J. Lucas,et al.  Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington’s disease , 2002, Brain Research.

[24]  T. Bisogno,et al.  Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease , 2001, Neuroreport.

[25]  T. Arzberger,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Normal Human Pituitary Gland and Pituitary Adenomas Express Cannabinoid Receptor Type 1 and Synthesize Endogenous Cannabinoids: First Evidence f , 2022 .

[26]  M. Glass.  The role of Cannabinoids in neurodegenerative diseases , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[27]  O. Hansson,et al.  Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice , 2001, The European journal of neuroscience.

[28]  D. Rubinsztein,et al.  The molecular biology of Huntington's disease , 2001, Psychological Medicine.

[29]  S B Dunnett,et al.  Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.

[30]  H. Robertson,et al.  Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice , 2000, Neuroscience.

[31]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.

[32]  Colin Blakemore,et al.  Delaying the onset of Huntington's in mice , 2000, Nature.

[33]  S. W. Davies,et al.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[34]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[36]  M. Herkenham,et al.  Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus , 1994, Annals of neurology.

[37]  J. Mandel,et al.  Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. , 1994, Journal of medical genetics.

[38]  R. Faull,et al.  Loss of cannabinoid receptors in the substantia nigra in huntington's disease , 1993, Neuroscience.

[39]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[40]  T. Bonner,et al.  Localization of cannabinoid receptor mRNA in rat brain , 1993, The Journal of comparative neurology.

[41]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Nicholson.  Processing human brain tissue for in situ hybridization with radiolabelled oligonucleotides. , 2002, International review of neurobiology.

[43]  Suzanne Imbriglio.  Environmental Enrichment Slows Disease Progression in R6/2 Huntingtonʼs Disease Mice. , 2002 .

[44]  B. Everitt,et al.  Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and µ-opioid receptor binding in the basal ganglia , 2000, Experimental Brain Research.

[45]  R. Faull,et al.  GABAa Receptor Subunit Subtypes in the Human Putamen and Globus Pallidus in Huntington’s Disease , 1996 .

[46]  R. Faull,et al.  GABA A RECEPTOR SUBUNIT SUBTYPES IN THE HUMAN PUTAMEN AND GLOBUS PALLIDUS IN HUNTINGTON'S DISEASE An in Situ Hybridization Study , 1996 .

[47]  M. Inase,et al.  The Basal Ganglia V , 1996, Advances in Behavioral Biology.

[48]  B. Morris,et al.  In situ hybridization protocols for the Brain , 1994 .

[49]  R. Faull,et al.  The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat. , 1993, Progress in brain research.